ArticleJournal of the American Society for Mass Spectrometry2026
Direct Comparison of MRM-MS and PRM-MS Methods for Quantitative Ganglioside Analysis.
Article in Journal of the American Society for Mass Spectrometry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MALDI-TOF Mass Spectrometry for Glioblastoma Secretome Biomarker Screening: A Review of Challenges and Perspectives.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gangliosides are structurally diverse, low-abundance glycosphingolipids central to neuronal signaling and cancer progression; however, their quantitative analysis is hindered by low ionization efficiency, structural heterogeneity, and complex isomeric patterns. Targeted mass spectrometry (MS) represents a powerful approach for resolving these challenges, yet systematic comparisons of multiple reaction monitoring (MRM) and parallel reaction monitoring (PRM) for native gangliosides remain limited. Here, we developed and optimized a targeted LC-MS/MS workflow to directly evaluate PRM on a Q-Exactive HF Orbitrap versus MRM on a TSQ Vantage triple quadrupole. Collision-energy optimization revealed distinct fragmentation behaviors across platforms, identifying optimal normalized collision energies (NCE) for PRM of 28 for GD1a and 25 for GD2, GT1b, GM1, and GQ1b, whereas optimal CE values for MRM were 35 for GD1a, GD2, and GT1b, and 30 for GQ1b. Additionally, PRM enabled multiplexing up to 15 transitions per analyte, improving signal-to-noise up to ∼4-fold and reducing %RSD through postacquisition transition summation. High-energy collision dissociation (HCD) used in PRM generated a richer array of fragment ions, including informative cross-ring cleavages and low-mass diagnostic ions, providing superior structural confidence compared to CID fragmentation in MRM. Notably, PRM uniquely enabled quantification of GM1, which exceeded the mass range of the triple quadrupole instrument. Applied to post-mortem human brain tissue extracts, PRM distinguished GD1a and GD1b isomers with high specificity. These findings establish PRM as a robust, highly sensitive, and structurally informative platform for comprehensive ganglioside profiling in complex biological matrices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.